<DOC>
	<DOCNO>NCT01341548</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy intranasally administer civamide nasal solution prevention cluster headache episodic cluster headache period .</brief_summary>
	<brief_title>Civamide Nasal Solution Cluster Headache</brief_title>
	<detailed_description>This double-blind , randomize , vehicle-controlled , parallel-group , multi-center , phase III efficacy safety study civamide nasal solution 0.01 % prevention cluster headache episodic cluster headache period . Approximately 180 subject ( 90 per treatment group ) , enrol randomized double-blind treatment either civamide nasal solution 0.01 % vehicle solution approximately 50 study site 2-5 subject randomize per enrol site . This study consist four period begin Screening Period , last minimum 1 day maximum 12 month , subject previously diagnose episodic cluster headache experience cluster headache await onset next episodic cluster headache period subsequent enrollment . The Screening Period follow 31-day study , consist 3-day Baseline Period may begin onset episodic cluster headache period end day prior initiating treatment ( Day -1 ) . Subjects return Visit 2 ( Day 1 , Pre-Dose ) Treatment Period begin , consist seven ( 7 ) day double-blind treatment . The Treatment Period immediately follow twenty-one ( 21 ) day Post-Treatment Observation Period .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Cluster Headache</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Capsaicin</mesh_term>
	<criteria>Written IRBapproved inform consent obtain sign , within 12 month enter Baseline Period ( Day 3 ) . Male female 18 year old . Subject â‰¥2 year history episodic cluster headache least 2 previous episodic cluster headache period . Cluster Headaches must meet following International Headache Society Diagnostic Criteria : Severe , unilateral , orbital , superorbital and/or temporal pain last 15 180 minute untreated . Headache associate least one follow present side pain : Conjunctival injection Lacrimation Nasal Congestion Rhinorrhea Forehead facial sweat Miosis Ptosis Eyelid edema A sense restlessness agitation The current episodic cluster headache period expect last least 5 week 24 week time entry Baseline Period ( Day 3 ) , base average duration subject 's usual episodic cluster headache period . At least one cluster headache ( 8 ) daily three day Baseline Period ( Days 3 , 2 , 1 ) immediately precede Study Day 1 . The subject generally good health , history episodic cluster headache . The subject agree begin new concurrent medication restrict medication participation study . All female childbearing potential must negative urine and/or serum pregnancy test prior entry Treatment Period . Females childbearing potential agree use approve form birth control abstain sexual activity study . Subject read write local language expect reliably follow study procedure . Clinical , historical previous laboratory evidence significant cardiovascular , renal , gastrointestinal , pulmonary , hepatic , endocrine , neurological ( include cluster headache ) , psychological , systemic disease , opinion investigator , might confound result study pose additional risk subject . Presence significant nasal disorder . Initiation medication , discontinuation medication change regimen exist medication ( ) therapies prophylaxis cluster headache 17 day prior enter Treatment Period ( Study Day 1 ) . Use systemic steroid treat current cluster headache episode . Use restrict medications/treatments within give time period prior Treatment Period throughout study ( Table 1 Protocol ) Subject difficulty distinguish his/her episodic cluster headache attack type headache , tension type headache . Presence chronic paroxysmal hemicrania , transform migraine , analgesic rebound headache . Females pregnant , breastfeeding , plan become pregnant study . Subject history alcohol and/or drug abuse within 12 month prior Screening Visit.. Subject know hypersensitivity contraindication use civamide , capsaicin , excipient clinical formulation . Subject participate another investigational study take another investigational drug within past 4 week . Subject participate prior efficacy study intranasal civamide : WL10010201 , WL10010202 , WL10010203 WL10010205 . ( This include subject enter screening period study WL10010201 , WL10010202 , WL10010203 WL10010205 randomize treatment ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Nasal</keyword>
	<keyword>Cluster Headache</keyword>
	<keyword>Episodic Cluster</keyword>
	<keyword>Headache</keyword>
	<keyword>Phase 3</keyword>
	<keyword>Civamide</keyword>
	<keyword>TRPV-1 Receptor</keyword>
</DOC>